Why Healthcare ETFs Are Hovering Around One-Year Highs

Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.

Zacks Investment Research • Oct 23, 2026

Biotech ETF (BBH) Hits New 52-Week High

For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.

Zacks Investment Research • Oct 21, 2026

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.

The Motley Fool • Oct 10, 2026

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.

The Motley Fool • Sep 24, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Zacks Investment Research • Sep 21, 2026

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, ​reinforcing the biotech pipeline for the fall IPO window.

Reuters • Sep 18, 2026

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

Seeking Alpha • Sep 18, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, 2011.

Zacks Investment Research • Sep 16, 2026

BBH: Biotech's Next Growth Cycle Is Just Getting Started

VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through diversified pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low yield, BBH's risk-reward profile is attractive given enduring demand and robust product pipelines.

Seeking Alpha • Aug 24, 2026

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio than VanEck Biotech ETF VanEck Biotech ETF focuses exclusively on 25 biotechnology stocks while State Street Health Care Select Sector SPDR ETF holds 60 diverse healthcare names State Street Health Care Select Sector SPDR ETF has demonstrated higher risk-adjusted growth and a smaller maximum drawdown over the last five years

The Motley Fool • Aug 5, 2026